"Avoidable Deaths" - Union for International Cancer Control

"Back to Basics: The Concept of HRQL Under a Magnifying Glass" - EORTC Quality of Life Group

"Bald for a Cause" initiative - UWC Dilijan College

Findings on the treatment of thyroid cancer and neuroblastoma in pediatric and adolescent patients - Hopp-Kindertumorzentrum Heidelberg

Françoise Meunier: Italian Senate unanimously approved the Right to be Forgotten for cancer survivors

Sarah Greene: Invigorating to be featured in the Swedish Foundation story about my endometrial cancer experience

Roupen Odabashian: Insightful talk on OncoDaily featuring Dr. Matteo Levisetti

Shushan Hovsepyan is appointed as Innovation and Development Director at IMMONC

Ruzanna Papyan: Discover the latest insights on improving adolescent and young adult care globally

Hagop Kantarjian

Nov 10, 2023

Blog Posts

Gevorg Tamamyan: Such an honor to be part of the great Society of Hematologic Oncology and to be the Ambassador of the Society to Armenia

Nov 6, 2023

Drugs

Hagop Kantarjian: Inotuzumab is safe and effective for the eradication of MRD in patients with B-cell ALL, with a MRD negativity rate of 69%

Acute Lymphocytic Leukaemia Hagop Kantarjian

Nov 4, 2023

Drugs

Vincent Rajkumar: How I treat newly diagnosed myeloma

Sep 27, 2023

Drugs

Hagop Kantarjian: Combination of venetoclax and hypomethylating agent provides high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated Acute Myeloid Leukemia.

Sep 12, 2023

Blog Posts

11 Tweets from SOHO23 not to miss.

Sep 9, 2023

Blog Posts

Jorge Cortes: It is an honor to receive this award named after a giant in leukemia research and a great mentor to me by another giant and mentor Hagop Kantarjian at the Society of Hematologic Oncology (SOHO).

Sep 6, 2023

Positive

Dr. Hagop Kantarjian received Emil J Freireich Distinguished Pioneer Award at the SOHO 2023

Sep 1, 2023

Drugs

Hagop Kantarjian: Now out in American Journal of Hematology reporting Ph II trial of CLIA +/- Sorafenib in newly diagnosed AML.

Aug 31, 2023

Insight

Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.

Aug 31, 2023

Career Updates

Naveen Pemmaraju: Wonderful MDACC MPN team farewell luncheon today in honor of Mary Ann Richie, our leader for MPN research RN group, as she retires from MD Anderson Cancer Center!